NO995852L - New form of S-omeprazole - Google Patents

New form of S-omeprazole

Info

Publication number
NO995852L
NO995852L NO995852A NO995852A NO995852L NO 995852 L NO995852 L NO 995852L NO 995852 A NO995852 A NO 995852A NO 995852 A NO995852 A NO 995852A NO 995852 L NO995852 L NO 995852L
Authority
NO
Norway
Prior art keywords
omeprazole
new form
new
Prior art date
Application number
NO995852A
Other languages
Norwegian (no)
Other versions
NO317518B1 (en
NO995852D0 (en
Inventor
Hanna Cotton
Anders Kronstroem
Anders Mattson
Eva Moeller
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO995852(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO995852D0 publication Critical patent/NO995852D0/en
Publication of NO995852L publication Critical patent/NO995852L/en
Publication of NO317518B1 publication Critical patent/NO317518B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
NO19995852A 1997-05-30 1999-11-29 New form of S-omeprazole, pharmaceutical composition containing it, process for its preparation, use thereof as well as intermediate and its preparation NO317518B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (en) 1997-05-30 1997-05-30 New association
PCT/SE1998/000974 WO1998054171A1 (en) 1997-05-30 1998-05-25 Novel form of s-omeprazole

Publications (3)

Publication Number Publication Date
NO995852D0 NO995852D0 (en) 1999-11-29
NO995852L true NO995852L (en) 2000-01-31
NO317518B1 NO317518B1 (en) 2004-11-08

Family

ID=20407186

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19995852A NO317518B1 (en) 1997-05-30 1999-11-29 New form of S-omeprazole, pharmaceutical composition containing it, process for its preparation, use thereof as well as intermediate and its preparation
NO2011010C NO2011010I1 (en) 1997-05-30 2011-06-07 Naproxen and esomeprazole tablets with modified release
NO2012011C NO2012011I1 (en) 1997-05-30 2012-06-05 Aspirin and esomeprazole magnesium trihydrate

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2011010C NO2011010I1 (en) 1997-05-30 2011-06-07 Naproxen and esomeprazole tablets with modified release
NO2012011C NO2012011I1 (en) 1997-05-30 2012-06-05 Aspirin and esomeprazole magnesium trihydrate

Country Status (44)

Country Link
US (6) US6369085B1 (en)
EP (2) EP0984957B3 (en)
JP (2) JP4002303B2 (en)
KR (2) KR100540720B1 (en)
CN (1) CN1161351C (en)
AR (2) AR012717A1 (en)
AT (2) ATE239011T1 (en)
AU (1) AU722839B2 (en)
BR (1) BR9809509A (en)
CA (2) CA2290963C (en)
CY (1) CY2012029I2 (en)
CZ (1) CZ297585B6 (en)
DE (3) DE69829511T2 (en)
DK (2) DK1273581T3 (en)
DZ (1) DZ2495A1 (en)
EE (1) EE03875B1 (en)
EG (1) EG24291A (en)
ES (2) ES2236407T3 (en)
HK (2) HK1051681A1 (en)
HR (1) HRP980263B1 (en)
HU (1) HU225987B1 (en)
ID (1) ID29306A (en)
IL (1) IL132947A0 (en)
IS (2) IS2142B (en)
LU (2) LU91871I2 (en)
MA (1) MA26500A1 (en)
ME (3) ME00198B (en)
MY (2) MY120745A (en)
NO (3) NO317518B1 (en)
NZ (1) NZ500991A (en)
PL (1) PL193546B1 (en)
PT (2) PT984957E (en)
RS (2) RS50005B (en)
RU (1) RU2184115C2 (en)
SA (2) SA98190280B1 (en)
SE (1) SE510650C2 (en)
SI (2) SI0984957T1 (en)
SK (2) SK285137B6 (en)
TN (1) TNSN98074A1 (en)
TR (1) TR199902934T2 (en)
TW (1) TW538040B (en)
UA (1) UA60334C2 (en)
WO (1) WO1998054171A1 (en)
ZA (1) ZA984179B (en)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
SE510650C2 (en) 1997-05-30 1999-06-14 Astra Ab New association
SE9900274D0 (en) 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DK1487818T3 (en) 2002-03-05 2007-08-20 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
CN100378093C (en) * 2002-06-27 2008-04-02 雷迪实验室有限公司 Method for preparing optical purity or optically concentrated sulfoxide compounds comprising amorphous esomeprazole and its salts
US7169793B2 (en) 2002-06-27 2007-01-30 Dr. Reddy's Laboratories Limited Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
EP1546131A1 (en) * 2002-08-30 2005-06-29 Dr. Reddy's Laboratories Ltd. Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
US8697094B2 (en) * 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
US20040235903A1 (en) * 2002-10-22 2004-11-25 Khanna Mahavir Singh Amorphous form of esomeprazole salts
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
WO2004060263A2 (en) * 2003-01-07 2004-07-22 Ranbaxy Laboratories Limited Magnesium salt of imidazole derivative
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
US20070060556A1 (en) 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100457104C (en) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 Alkaline salts of proton pump inhibitors
ES2302007T3 (en) * 2003-07-23 2008-07-01 Nycomed Gmbh ALKALINE SALTS OF PROTON PUMP INHIBITORS.
SE0302381D0 (en) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (en) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1715854A2 (en) * 2004-02-18 2006-11-02 Allergan, Inc. Prodrugs for the intravenous administration of proton pump inhibitors
US20070060621A1 (en) * 2004-02-18 2007-03-15 Hughes Patrick M Methods and compositions for the administration of prodrugs of proton pump inhibitors
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
EP1765806A1 (en) * 2004-06-24 2007-03-28 AstraZeneca AB New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
ES2246149B1 (en) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. SOLID FORMS OF S-OMEPRAZOL MAGNETIC SALT AND PROCEDURES FOR PREPARATION.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (en) 2005-03-03 2007-11-01 Esteve Quimica, S.A. PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
WO2006120520A1 (en) * 2005-05-06 2006-11-16 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
EP1891043A1 (en) 2005-06-15 2008-02-27 Hetero Drugs Limited Amorphous esomeprazole hydrate
WO2007008588A2 (en) * 2005-07-07 2007-01-18 Dr. Reddy's Laboratories Ltd. Omeprazole form b
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (en) 2005-07-28 2006-11-01 한미약품 주식회사 Process of esomeprazole and salts thereof
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
JP5017274B2 (en) * 2005-10-26 2012-09-05 ハンミ・サイエンス・カンパニー・リミテッド S-omeprazole strontium salt or hydrate thereof, process for producing the same, and pharmaceutical composition containing the same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (en) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 Prepn process of [(substituted pyridyl) methyl] sulfenyl-1H-benzimidazole compound and its antimer zinc salt
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
WO2007148213A2 (en) * 2006-06-21 2007-12-27 Glenmark Pharmaceuticals Limited Novel polymorph of esomeprazole potassium and process for its preparation
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EA200900985A1 (en) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место METHOD OF OBTAINING OPTICAL PURE OMEPRAZOL
NZ579136A (en) * 2007-02-21 2012-05-25 Cipla Ltd Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (en) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 Improved preparing method of (S)-omeprazole from omeprazole racemate using optical resolution agent
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2008149204A1 (en) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (en) * 2007-08-29 2012-06-15 Univ Rouen PROCESS FOR DEDOLDING SALTS OF OMEPRAZOLE
EP2195309A4 (en) * 2007-10-08 2013-04-24 Hetero Drugs Ltd Polymorphs of esomeprazole salts
RU2013106514A (en) 2007-10-12 2015-03-10 Такеда Фармасьютикалз Норт Америка, Инк. METHODS FOR TREATING GASTROINTESTINAL DISORDERS INDEPENDENTLY ON FOOD CONSUMPTION
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr Preparation of esomeprazole magnesium and hydrates thereof
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CN101391993B (en) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 Method for preparing S-omeprazole and salt thereof by forming inclusion complex with (S)-(-)-1,1'-dinaphthalene-2,2'-diol
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010150276A2 (en) * 2009-06-02 2010-12-29 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
EA021112B1 (en) * 2009-06-25 2015-04-30 Поузен Инк. Method for treating pain and/or inflammation in a patient in need of aspirin therapy
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
WO2011058569A1 (en) 2009-11-12 2011-05-19 Hetero Research Foundation Process for the resolution of omeprazole
EP2510089B1 (en) 2009-12-08 2015-10-21 Codexis, Inc. Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (en) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese PRECURSOR PHASE AND USE THEREOF FOR PREPARING MAGNESIUM TETRAHYDRATE SALT OF AN OMEPRAZOLE ENANTIOMER
CN102241668B (en) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 Esomprazole salt
HUE037616T2 (en) 2010-12-08 2018-09-28 Codexis Inc Biocatalysts and methods for the synthesis of armodafinil
CN102757421A (en) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 Purification method of esomeprazole
CN102911158B (en) * 2011-07-31 2015-07-22 连云港润众制药有限公司 Crystal form of esomeprazole magnesium
CN102936238B (en) * 2011-11-25 2015-02-18 成都自豪药业有限公司 New crystal form of S-omeprazole magnesium salt and preparation method thereof
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN102584792B (en) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 Method for preparing high-purity esomeprazole
CN102993184A (en) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 Esomeprazole and preparation method of magnesium trihydrate of esomeprazole
CN104250243B (en) * 2013-06-27 2016-12-28 四川国为制药有限公司 A kind of preparation method of Esomeprazole magnesium dihydrate A crystal formation
CN103570686B (en) * 2013-10-14 2015-04-01 哈药集团技术中心 Method for synthesizing and refining esomeprazole sodium
CN104725357A (en) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 Preparation method of esomeprazole magnesium dihydrate crystal form B
FR3018812A1 (en) * 2014-03-21 2015-09-25 Minakem NOVEL INTERMEDIATE PHASE OF FORM A OF MAGNESIUM SALT DIHYDRATE OF AN OMEPRAZOLE ENANTIOMER
CN104447699A (en) * 2014-12-10 2015-03-25 哈药集团技术中心 Preparation method of esomeprazole magnesium trihydrate
CN105111188B (en) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 A kind of preparation method of esomeprazole magnesium trihydrate crystal formation
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (en) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 A kind of esomeprazole magnesium crystal-form compound and preparation method thereof
KR102080023B1 (en) 2018-01-29 2020-02-21 주식회사 종근당 Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
KR102006777B1 (en) 2018-01-29 2019-10-08 주식회사 종근당 Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
KR102432084B1 (en) 2021-11-16 2022-08-12 알리코제약(주) S-omeprazole tablet having improved stability and miniaturized size
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
SE8301182D0 (en) 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
US5244891A (en) * 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE4035455A1 (en) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab ENANTIOMER SEPARATION
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
FR2719045B1 (en) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Process for the preparation of L-aspartic acid from ammonium aspartate.
FR2722191B1 (en) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE
UA41946C2 (en) 1994-07-08 2001-10-15 Астра Актієболаг Oral pharmaceutical tablet compound dosage form, method for manufacture, blister package, and method for inhibiting acid secretion in stomach and/or treating gastrointestinal inflammatory diseases
SE504459C2 (en) 1994-07-15 1997-02-17 Astra Ab Process for the preparation of substituted sulfoxides
EP0792879B1 (en) * 1994-11-14 2001-02-28 Daiichi Pharmaceutical Co., Ltd. Process for preparing 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (en) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (en) 1995-05-25 1999-03-10 常州市第四制药厂 Aomeilazole salt hydrate for gastric acid inhibitor and its preparing method
SE9600070D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600072D0 (en) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US6747155B2 (en) * 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (en) 1997-05-30 1999-06-14 Astra Ab New association
AR057181A1 (en) 2005-11-30 2007-11-21 Astra Ab NEW COMBINATION DOSAGE FORM

Also Published As

Publication number Publication date
DE69814069T3 (en) 2014-03-27
SK162599A3 (en) 2000-06-12
PT1273581E (en) 2005-06-30
WO1998054171A1 (en) 1998-12-03
US6677455B2 (en) 2004-01-13
KR100527804B1 (en) 2005-11-15
AR012717A1 (en) 2000-11-08
NO2011010I1 (en) 2011-06-20
EP1273581B1 (en) 2005-03-23
US20020198239A1 (en) 2002-12-26
JP2007161734A (en) 2007-06-28
IS5272A (en) 1999-11-25
PT984957E (en) 2003-07-31
EP0984957A1 (en) 2000-03-15
EP1273581A1 (en) 2003-01-08
KR100540720B1 (en) 2006-01-12
ID29306A (en) 2001-08-16
ME00198B (en) 2011-02-10
US6369085B1 (en) 2002-04-09
AR059589A2 (en) 2008-04-16
CN1258295A (en) 2000-06-28
ES2195345T7 (en) 2014-01-15
US20080255363A1 (en) 2008-10-16
DE69829511D1 (en) 2005-04-28
US20120252847A1 (en) 2012-10-04
DK1273581T3 (en) 2005-06-06
NZ500991A (en) 2001-05-25
CN1161351C (en) 2004-08-11
PL193546B1 (en) 2007-02-28
US7411070B2 (en) 2008-08-12
MEP18008A (en) 2010-10-10
TNSN98074A1 (en) 2005-03-15
ES2236407T3 (en) 2005-07-16
JP2002501529A (en) 2002-01-15
SI1273581T1 (en) 2005-08-31
SK285137B6 (en) 2006-07-07
US20050075369A1 (en) 2005-04-07
EG24291A (en) 2009-01-08
ES2195345T3 (en) 2003-12-01
BR9809509A (en) 2000-06-20
EP0984957B3 (en) 2013-09-18
DE122012000017I1 (en) 2012-08-16
CA2290963A1 (en) 1998-12-03
US7745466B2 (en) 2010-06-29
CA2521391C (en) 2009-09-29
HRP980263B1 (en) 2002-02-28
MEP24908A (en) 2010-10-10
NO2012011I1 (en) 2012-06-18
SA05260296B1 (en) 2008-04-16
ATE291574T1 (en) 2005-04-15
RS50005B (en) 2008-09-29
TR199902934T2 (en) 2000-04-21
LU91871I2 (en) 2011-11-21
MY120745A (en) 2005-11-30
US20110130570A1 (en) 2011-06-02
SE9702065L (en) 1998-12-01
HRP980263A2 (en) 1999-02-28
MA26500A1 (en) 2004-12-20
EE03875B1 (en) 2002-10-15
DE69814069T2 (en) 2004-04-01
CY2012029I1 (en) 2015-08-05
ZA984179B (en) 1998-11-30
IS8368A (en) 2006-03-22
SE9702065D0 (en) 1997-05-30
NO317518B1 (en) 2004-11-08
SK284837B6 (en) 2005-12-01
YU60999A (en) 2002-03-18
JP4002303B2 (en) 2007-10-31
ATE239011T1 (en) 2003-05-15
SE510650C2 (en) 1999-06-14
HUP0001849A2 (en) 2002-05-29
IS2774B (en) 2012-03-15
HU0001849D0 (en) 2002-05-29
HK1025962A1 (en) 2000-12-01
IS2142B (en) 2006-09-15
HU225987B1 (en) 2008-02-28
IL132947A0 (en) 2001-03-19
RS50067B (en) 2009-01-22
SI0984957T1 (en) 2003-10-31
RU2184115C2 (en) 2002-06-27
NO995852D0 (en) 1999-11-29
UA60334C2 (en) 2003-10-15
PL337180A1 (en) 2000-08-14
RS20070459A (en) 2008-06-05
US8466175B2 (en) 2013-06-18
EP0984957B1 (en) 2003-05-02
AU7793598A (en) 1998-12-30
CZ297585B6 (en) 2007-01-10
KR20010013126A (en) 2001-02-26
DZ2495A1 (en) 2003-01-25
SA98190280B1 (en) 2006-07-04
HUP0001849A3 (en) 2003-02-28
MY127793A (en) 2006-12-29
KR20050042827A (en) 2005-05-10
CA2521391A1 (en) 1998-12-03
LU92017I2 (en) 2012-08-06
US8076361B2 (en) 2011-12-13
CY2012029I2 (en) 2015-08-05
DK0984957T3 (en) 2003-06-30
DE69814069D1 (en) 2003-06-05
HK1051681A1 (en) 2003-08-15
EE9900550A (en) 2000-06-15
DE69829511T2 (en) 2006-02-16
WO1998054171A8 (en) 1999-12-23
CA2290963C (en) 2006-03-28
AU722839B2 (en) 2000-08-10
TW538040B (en) 2003-06-21

Similar Documents

Publication Publication Date Title
NO995852D0 (en) New form of S-omeprazole
NO993068D0 (en) New form of connection
FI974139A0 (en) Foerfarande Foer modifiering av Cellulosa
ID27092A (en) MAKING OF ANHYDRIDAL FTALATES
ID24481A (en) BENZAMIDA MONOSICLIC GASTROCINETICS OF DERIVATES-3-OR-SUBSTITUTED 4- (AMINOMETHL) -PIPERIDINS
ID24458A (en) MODIFICATION OF IN-SITO POLYLEFINE RHEOLOGY
EE04154B1 (en) Method of preparation of omeprazole
FI974023A0 (en) Taetningskonstruktion Foer suglaogan av en sugvals i en pappersmaskin / en kartongmaskin
NO995796D0 (en) New procedure
ID28032A (en) TRICICLIC OF PIPERIDIN-Δ3-AS ANTAGONIS-α2
PT964867E (en) ANTAGONISTS OF THE TAQUICINIMA
NO996438D0 (en) New combination of asthma drugs
FI972800A0 (en) Behandling av signaleringsmeddelande i ATM-nod
ID19540A (en) METHOD OF MAKING BENZOFENON DECREASES
NO20014845D0 (en) Use of arylalkanoylpyridazines
FI973582A0 (en) Maetning av faedningsmarginal i radiosystem
FI974235A0 (en) New methods of administration
FI974508A (en) Type of device
FI971730A0 (en) Munstyckesarrangemang i blaoslaodan av en pappersmaskin
FI973860A0 (en) Foerfarande Foer saekerstaellande av noedkommunikation i en kedjad V5-aslutning
FI972847A0 (en) Foerfarande Foer hantering av aonga i en fibreringsprocess
FI973311A0 (en) Foerfarande Foer foermedling av protoken Foer V5-enslutningar i en kedjad V5-anslutning
FI974311A0 (en) Foerfarande Foer centralisering av abonnenter i en lokalcentral
NO995269D0 (en) Use of immunomodulatory agents
UA2221S (en) SET OF SPECIAL CLOTHING

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: VIMOVO; NAT. REG. NO/DATE: 09-7130 20101207; FIRST REG. NO/DATE: GB , PL17091/0263-0001 20101105

Spc suppl protection certif: 2011010

Filing date: 20110607

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: AXANUM; NAT. REG. NO/DATE: 10-7602 20120106; FIRST REG. NO/DATE: PT , 5402359,5402367,5402375 20110812

Spc suppl protection certif: 2012011

Filing date: 20120605

LC4 Limitation of patent rights - b3 (par. 39b patent act)

Effective date: 20130325

MK1K Patent expired